The Europe Narcolepsy Therapeutics Market would witness market growth of 9.1% CAGR during the forecast period (2022-2028).
Narcolepsy frequently causes the most difficulties and is the first symptom to manifest, making it challenging to focus on particular tasks. Other signs include a sudden, waking muscular weakness that renders a person immobile or lame. Although narcolepsy is a chronic condition that cannot be fully treated, the symptoms can gradually become better with the right drugs and a lifestyle change.
Individuals who experience more stress live stressful lives as a result, which raises their risk of developing narcolepsy by increasing their use of dangerous addictive like alcohol, tobacco, and other substances. Over the past few years, narcolepsy drug development has accelerated significantly. Narcoleptics have a strong want to sleep and are low on energy. Cataplexy is an abrupt loss of muscle tone and weakness that might last for a few seconds or several minutes.
This is the first face-to-face survey conducted across the entire country of Germany on the prevalence of clearly characterized severe insomnia and how it affects people's quality of life. The survey was a component of an epidemiological investigation that was also carried out in Sweden, Belgium, Great Britain, and Ireland. The quota approach was used to interview a representative sample of 1913 adults in all regions of Germany who were at least 18 years old. The fourth revision of the Diagnostic and Statistical Manual of Mental Diseases' primary criteria for severe insomnia was used to determine which subjects met the criteria for symptomatic insomnia (DSM-IV).
The Germany market dominated the Europe Narcolepsy Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $361.2 million by 2028.The UK market is anticipated to grow at a CAGR of 8.2% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 9.9% during (2022 - 2028).
Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Narcolepsy Therapeutics Market will Hit $5 Billion by 2028, at a CAGR of 10.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Narcolepsy with Cataplexy
- Narcolepsy Without Cataplexy
- Secondary Narcolepsy
By Product
- Sodium Oxybate
- Selective Serotonin Reuptake Inhibitor
- Central Nervous System Stimulants
- Tricyclic Antidepressants
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Jazz Pharmaceuticals plc
- Shionogi & Co., Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
- Bioprojet
- Takeda Pharmaceutical Company Limited
- Ligand Pharmaceuticals, Inc.
- Graymark Healthcare, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Narcolepsy Therapeutics Market, by Type
1.4.2 Europe Narcolepsy Therapeutics Market, by Product
1.4.3 Europe Narcolepsy Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Narcolepsy Therapeutics Market by Type
3.1 Europe Narcolepsy with Cataplexy Market by Country
3.2 Europe Narcolepsy Without Cataplexy Market by Country
3.3 Europe Secondary Narcolepsy Market by Country
Chapter 4. Europe Narcolepsy Therapeutics Market by Product
4.1 Europe Sodium Oxybate Market by Country
4.2 Europe Selective Serotonin Reuptake Inhibitor Market by Country
4.3 Europe Central Nervous System Stimulants Market by Country
4.4 Europe Tricyclic Antidepressants Market by Country
4.5 Europe Others Market by Country
Chapter 5. Europe Narcolepsy Therapeutics Market by Country
5.1 Germany Narcolepsy Therapeutics Market
5.1.1 Germany Narcolepsy Therapeutics Market by Type
5.1.2 Germany Narcolepsy Therapeutics Market by Product
5.2 UK Narcolepsy Therapeutics Market
5.2.1 UK Narcolepsy Therapeutics Market by Type
5.2.2 UK Narcolepsy Therapeutics Market by Product
5.3 France Narcolepsy Therapeutics Market
5.3.1 France Narcolepsy Therapeutics Market by Type
5.3.2 France Narcolepsy Therapeutics Market by Product
5.4 Russia Narcolepsy Therapeutics Market
5.4.1 Russia Narcolepsy Therapeutics Market by Type
5.4.2 Russia Narcolepsy Therapeutics Market by Product
5.5 Spain Narcolepsy Therapeutics Market
5.5.1 Spain Narcolepsy Therapeutics Market by Type
5.5.2 Spain Narcolepsy Therapeutics Market by Product
5.6 Italy Narcolepsy Therapeutics Market
5.6.1 Italy Narcolepsy Therapeutics Market by Type
5.6.2 Italy Narcolepsy Therapeutics Market by Product
5.7 Rest of Europe Narcolepsy Therapeutics Market
5.7.1 Rest of Europe Narcolepsy Therapeutics Market by Type
5.7.2 Rest of Europe Narcolepsy Therapeutics Market by Product
Chapter 6. Company Profiles
6.1 Jazz Pharmaceuticals plc
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Approvals and Trials:
6.2 Shionogi & Co., Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expenses
6.3 Teva Pharmaceutical Industries Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional & Segmental Analysis
6.4.4 Research & Development Expense
6.5 Bioprojet
6.5.1 Company Overview
6.5.2 Recent strategies and developments:
6.5.2.1 Partnerships, Collaborations, and Agreements:
6.6 Takeda Pharmaceutical Company Limited
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.7 Ligand Pharmaceuticals, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Graymark Healthcare, Inc.
6.8.1 Company Overview
TABLE 1 Europe Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 2 Europe Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 3 Europe Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 4 Europe Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 5 Europe Narcolepsy with Cataplexy Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Narcolepsy with Cataplexy Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Narcolepsy Without Cataplexy Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Narcolepsy Without Cataplexy Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Secondary Narcolepsy Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Secondary Narcolepsy Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 12 Europe Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 13 Europe Sodium Oxybate Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Sodium Oxybate Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Selective Serotonin Reuptake Inhibitor Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Selective Serotonin Reuptake Inhibitor Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Central Nervous System Stimulants Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Central Nervous System Stimulants Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Tricyclic Antidepressants Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe Tricyclic Antidepressants Market by Country, 2022 - 2028, USD Million
TABLE 21 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Narcolepsy Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Narcolepsy Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 25 Germany Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 26 Germany Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 27 Germany Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 28 Germany Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 29 Germany Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 30 Germany Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 31 UK Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 32 UK Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 33 UK Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 34 UK Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 35 UK Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 36 UK Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 37 France Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 38 France Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 39 France Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 40 France Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 41 France Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 42 France Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 43 Russia Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 44 Russia Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 45 Russia Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 46 Russia Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 47 Russia Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 48 Russia Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 49 Spain Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 50 Spain Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 51 Spain Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 52 Spain Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 53 Spain Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 54 Spain Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 55 Italy Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 56 Italy Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 57 Italy Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 58 Italy Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 59 Italy Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 60 Italy Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 61 Rest of Europe Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 62 Rest of Europe Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 63 Rest of Europe Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 64 Rest of Europe Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 65 Rest of Europe Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 66 Rest of Europe Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 67 Key Information – Jazz Pharmaceuticals plc
TABLE 68 Key Information – Shionogi & Co., Ltd.
TABLE 69 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 70 Key Information – Pfizer, Inc.
TABLE 71 Key Information – Bioprojet
TABLE 72 Key Information – Takeda Pharmaceutical Company Limited
TABLE 73 Key Information – Ligand Pharmaceuticals, Inc.
TABLE 74 Key Information – Graymark Healthcare, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Jazz Pharmaceuticals PLC